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ABSTRACT 
Children born to human immunodeficiency virus type 1 (HIV-1) infected women are 
more vulnerable to infections and are more likely to die even when they are not HIV-1 
infected. These adverse outcomes may blunt any gains made in escaping HIV-1 infection and 
could be ameliorated by improving maternal antibody transfer to the baby. The overall aim of 
this thesis was to study the role of antiretroviral prophylaxis and breastfeeding practices on 
maternal antibody transfer to their children and on the morbidity these children experience in 
the first year of life . 
Studies I and II examined the influence of antiretroviral treatment on antibody levels 
during pregnancy and delivery, in cord blood and breast milk. We used data from a 
randomized clinical trial in which HIV-1 infected pregnant women with CD4 counts between 
200 and 500 were randomized to short-course zidovudine (ZDV) or triple antiretroviral 
therapy (ART) during pregnancy for prevention of HIV-1 transmission from mother to child. 
Antibody levels against measles, pneumococcus and rotavirus were measured in maternal 
plasma, infant cord blood and breast milk and compared between the trial arms. We found 
that maternal levels in plasma (Study I) and breast milk (Study II) were comparable between 
the two groups. Compared to women on short-course ZDV, women on triple ART transferred 
higher amounts of antibody via the placenta. 
In Study III, we compared infant morbidity, hospitalization, and mortality during the 
first year of life of HIV-1 exposed uninfected (HEU) children born to the women in Study I 
and II.  Our morbidity outcomes of interest were those that cause significant mortality in 
these children namely diarrhea, pneumonia, and lower respiratory tract infection, and a 
composite measure of any infectious morbidity. We found important predictors for mortality 
in these children; however, we found no effect of the mother’s ART treatment regimen for 
any of these outcomes. 
Study IV used a real world setting in which HIV-1 infected women were enrolled 
during pregnancy into a clinic-level, before-after breastfeeding counseling intervention study. 
Women in the intervention arm were offered three counseling sessions that promoted 
exclusive breastfeeding (EBF), explained breastfeeding techniques and described its benefits. 
EBF prevalence was comparable between the two arms at 14 weeks postpartum. We found no 
differences between the groups for 6-week HIV-free survival or 14-week infant survival for 
the children born to these women. 
  
The results of this thesis show some benefit for maternal triple ART compared to 
short-course ZDV in passive antibody transfer via the placenta and that high EBF rates are 
attainable. The non-significant findings for impact on morbidity and mortality outcomes 
among HEU children highlight the complexity of unravelling the mechanisms that underlie 
the higher vulnerability that has been observed in these children. The findings from this thesis 
may be used to inform the design of future studies so that ultimately the health and survival 
of HEU children can be secured. 
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1 INTRODUCTION 
As a result of life-saving antiretroviral therapy (ART) and a better understanding of the 
transmission dynamics of maternally acquired human immunodeficiency virus type 1 (HIV-
1), the pediatric HIV-1 burden has significantly and elimination of vertical transmission my 
be within reach. From a peak of more than 40% of children born to HIV infected women 
becoming infected in the pre-ART era[1], increased access to and uptake of interventions to 
prevent mother to child transmission (PMTCT) of HIV-1 have resulted in transmission rates 
below 1%  and about 1% in non-breastfeeding and breastfeeding populations, respectively[2, 
3]. With continuing expansion of PMTCT coverage, the number of infected children is 
shrinking. However, the population of children exposed to HIV-1 and to antiretroviral (ARV) 
medication but born uninfected is growing.  
While initial efforts were rightly focused on prevention of pediatric HIV, it is increasingly 
being recognized that HIV-exposed uninfected (HEU) children merit special attention due to 
their susceptibility to infectious morbidity and mortality that blunt the gains achieved by 
averting HIV-1 infection[4-7]. Epidemiological studies of the contribution of HIV exposure 
in this HEU infant population pose a number of challenges. Earlier in the HIV epidemic, 
definitive HIV-1 infection status in either mother or child was challenging because 1) of lack 
of repeated testing of women who initially tested negative antenatally, and 2) antibody based 
HIV diagnosis in children, making it difficult to measure the contribution of HIV exposure 
with precision. In more contemporary studies, it is impossible to disentangle the effects of 
dual exposures to HIV and ART. In both eras, challenges to the interpretation of data 
collected from studies include a lack of a suitable unexposed uninfected comparison group, 
differences in breastfeeding uptake, intensity and duration, and incomplete consideration of 
the underlying web of environmental, behavioral, socioeconomic and health system factors 
that universally affect child survival, but may have a greater impact for HEU children[5, 8]. 
In spite of these challenges, we sought to understand the increased morbidity and mortality 
among HEU children in this thesis. In particular, we focused on the contribution of improved 
suppression of maternal HIV-1 to infant health. We compared immunologic outcomes of 
infants born to women who received triple ART administered during pregnancy and 
breastfeeding in comparison to the then standard of care comprising of short course 
monotherapy administered during pregnancy and delivery. In addition, we investigated 
whether breast milk benefits could be increased via improved breastfeeding practices. 
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2 BACKGROUND  
2.1 PREVALENCE OF HIV-1 GLOBALLY, IN SUB-SAHARAN AFRICA AND 
KENYA 
HIV-1 infection is one of the greatest health challenges the world has faced. However, 
due to concerted global prevention and treatment efforts, remarkable gains have been made in 
decreasing HIV-1-related deaths and new infections. Annual HIV-related deaths have 
reduced by half from the peak in 2004 to about 940,000 in 2017, and new infections have 
almost halved from the peak in 1996 to 1.8 million in 2017[9]. This public health success of a 
fast decline in HIV related deaths with a slower decline in new infections has resulted in 
more  people living with HIV. In 2017, there were 36.9 million people living with HIV in 
2017, 53% of whom live in sub-Saharan Africa (SSA). Unlike outside SSA where the 
majority of adults living with HIV are men, in SSA, the majority of HIV-positive adults are 
reproductive-age women who continue to disproportionately account for a large percentage 
of new adult infections (59% in 2017).  Adolescent girls and young women are particularly 
vulnerable, with three out of every four new infections in adolescents aged 15-19 years in 
SSA being girls, and compared to young men, 15-24 year old young women are twice as 
likely to be living with HIV[9].  
Kenya is a success story in the remarkable progress it has made in its response to 
HIV. However, the disease burden is still among the highest in the world with an adult 
prevalence of 4.9%[10].  Its profile mirrors that of SSA in that it is a generalized epidemic 
with higher adult prevalence among women. Of the 1.5 million Kenyan adults living with 
HIV-1 in 2017, 62% were women, and a third of all new infections in adults occurred in 15-
24 year old adolescent girls. Within the country there are regional differences, with some 
counties having an adult prevalence >20% while it is <0.1% in other areas. Eight of the 47 
counties contribute to more than 50% of people living with HIV-1 in the country[10]. Nairobi 
and Mombasa, where the studies reported in this thesis were conducted, are among the 8 
counties with a large HIV-1 burden. Although their adult HIV-1 prevalence decreased 
between the time the studies were conducted until 2017, going from 8.8% and 8.1% to 6.1% 
and 4.1%, respectively, it still remains high[10].  
2.2 MOTHER TO CHILD TRANSMISISON OF HIV-1 GLOBALLY AND IN 
KENYA 
 The high HIV-1 burden among reproductive age women results in a large number of 
children exposed to HIV-1 in utero, intra-partum and post-natally through breastfeeding. 
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More than 1 million children are born to these women every year. However, with the 
remarkable success in improved access to interventions such as ARVs, either as prophylaxis 
to prevent transmission of HIV-1 from mother to child, or treatment for their own health, the 
number of infections occurring among children born to these women have reduced 
dramatically from about 300,000 in 2010 to about 110,000 in 2017[9, 11]. In 2011, targets to 
eliminate pediatric HIV were set by the World Health Organization (WHO). A few countries 
have already been certified as having eliminated mother to child transmission (MTCT) of 
HIV-1 (defined as transmission rates below 5% in breastfeeding populations and below 2% in 
non-breastfeeding populations) (Figure 1), and many are working to achieve the 2030 
elimination targets set by WHO[12].   
 
Figure 1: Mother to child HIV-1 transmission rates for select countries in 2016 
With a majority of low and middle income countries now offering lifelong antiretroviral 
treatment (ART) to HIV infected pregnant and breastfeeding women as soon as the HIV-1 
diagnosis is made, a majority of their infants will not become infected (Figure 2). However, 
this progress means that there is an increasingly large number of children exposed to HIV and 
ARVs who remain uninfected. Although they have escaped HIV infection, these children 
have special health and developmental needs. 
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Figure 2 Global PMTCT coverage and estimated MTCT in 2016 
2.3 MORTALITY AND MORBIDITY AMONG HIV-1 EXPOSED UNINFECTED 
CHILDREN 
Although some studies have reported no increase in mortality risk[13, 14], most 
evidence points to a higher morbidity and mortality risk for HEU children compared to HIV 
unexposed uninfected children (HUU)[15-20]. HEU children appear to be at a higher risk for 
infection and death in the presence of advanced maternal HIV-1 characterized by low CD4 
count, high HIV-1 viral load, and symptomatic HIV-1 disease factors which have been 
demonstrated in several studies to be associated with worse infant outcomes[21-24].  The 
mortality risk among these children is especially high in the first year of life compared to 
children born to (HIV-1) uninfected women, with HEU children having up to a 4-times 
higher  mortality[15, 23, 25-28].  HEU children in low-resource settings are at an even higher 
risk for infectious morbidity and mortality outcomes[29-32]  
While multiple factors have been proposed as explanations for the higher morbidity 
and mortality risk from infectious causes, including social and behavioral factors, it is thought 
that immunological alterations due to HIV-1 (and possibly ARV) exposure in utero have a 
part to play (Figure 3). 
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Figure 3 Morbidity and mortality vulnerability cascade in HEU children[4] 
 In these HIV-1-exposed infants, the commonest causes of death are the same as in 
any young children, namely pneumonia, diarrhea, sepsis and other invasive bacterial and viral 
infections [25, 33] in which acute respiratory infections and diarrheal disease account for a 
large proportion of these deaths (Figure 4). These are conditions for which a child may 
receive some protection from passive immunity obtained via trans-placental and breast milk 
transfer of maternal antibodies [34, 35]. However, in HIV-1 infected individuals, there is 
defective memory B cell function resulting in suboptimal antigen-specific antibody 
production[36]. In addition, abnormal immunoglobulin G (IgG) production by hyperactivated 
naïve B cells produces a hyper-gammaglobulinemic state. The combination of these and other 
factors such as placental malaria, and infant factors such as gestational age and birthweight 
result in inefficient transfer of pathogen specific antibodies across the placenta[37-40], while 
large amounts of non-specific antibodies are transferred.  Therefore, although HEU infants 
have higher immunoglobulin levels compared to HUU infants, among infants born to 
antiretroviral naïve women with high maternal systemic viral load, pathogen specific 
antibody levels are found to be lower [41]. These low levels of pathogen specific antibodies 
may explain some of the high mortality experienced during infancy by HEU children and 
particularly in early postnatal life before they build their own immunity to pathogens in their 
immediate environment. 
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Figure 4 Distribution of causes of death in children below 5 years of age by region in 
2015[42]  
In infants born to antiretroviral naïve HIV-1 infected women, low levels of specific 
antibodies have been demonstrated for several pathogens, including tetanus, measles virus, 
Streptococcus. pneumoniae, and others [40, 43-46]. A recent pooled analysis in which 80% 
of the women did not receive ARVs, or received mono or dual prophylaxis, suggests that 
maternal ART and breastfeeding are significant contributors to survival in HEU children[20]. 
However, it is not known whether providing triple ART to HIV-1 infected pregnant women 
becomes a game changer for their children [47, 48] particularly with regard to pneumonia, 
diarrhea, and sepsis which cause the most deaths during infancy.  In our studies, we focused 
on measles, S. pneumoniae and rotavirus due to their significant direct and indirect 
contribution to diarrhea and pneumonia morbidity and mortality among young children. 
2.3.1 Streptococcus pneumoniae disease  
 
Streptococcus pneumoniae is an important cause of bacterial pneumonia, 
meningitis, and sepsis in children and is estimated to cause 14.5 million cases worldwide  
and  700,000 to 1 million deaths in children under the age of 5 each year [49]. Of the 
different clinical illnesses caused by this bacteria, pneumonia is the most common form 
(96% of cases) of serious pneumococcal disease, and accounts for 17% of child deaths in 
developing countries, making it a leading cause of death among young children [42].  
For a long time, the burden of disease due to S. pneumonia in developing countries 
went unrecognized. However, a meta-analysis conducted to determine the global burden of 
disease due to S. pneumonia found that between 1980 and 2005, Africa had both the largest 
number of total deaths from pneumococcal disease and the highest rate of pneumococcal 
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mortality as a result of both a high incidence rate (3627 per 100,000), and the highest 
overall case-fatality rate (399 per 100,000)[50]. The magnitude of this problem is further 
borne out by the fact that only ten countries, all in Africa and Asia, account for 61% of all 
pneumococcal deaths worldwide and a similar number of countries also in Africa and Asia, 
account for 66% of all pneumococcal cases.  Although these deaths occur via any of the 
three serious clinical syndromes, namely pneumonia, meningitis, and non-pneumonia non-
meningitis invasive disease, almost all the deaths (90%) are due to pneumococcal 
pneumonia [50]. The incidence of pneumococcal meningitis among all children below 5 
years of age is low (0.7% of pneumococcal disease compared to 96% for pneumococcal 
pneumonia). However, the case fatality is high, especially in Africa where it is 73%, 
making it an important cause of death in this age group. 
In addition to primary infections, S. pneumoniae is a common secondary infection 
being the most commonly identified organism found in 30% to 50% of all 
microbiologically confirmed tests in measles-related pneumonia deaths [51, 52] as well as a 
common secondary bacterial infection in unvaccinated children infected with respiratory 
viruses[53]. The burden of pneumococcal disease and adverse outcomes is of special 
significance for HEU infants who are more likely to experience at least one episode of 
pneumonia in the first two years of life than HUU infants [54, 55], and are more likely to 
experience treatment failure and death following a pneumonia episode, especially in the 
first 6 months of life [32]. It is therefore likely that HEU children disproportionately 
contribute to the high mortality from pneumonia in African children under 5 years of age. 
Although there are other pathogens involved in childhood pneumonia among HEU infants, 
the existence of a safe and effective vaccine makes prevention of morbidity and mortality 
due to S. pneumoniae a meaningful target. Prevention of pneumococcal disease would 
greatly accelerate progress towards achieving the ambitious global target of reducing the 
mortality rate in children younger than 5 years to 25 or fewer deaths per 1,000 live births by 
2030[42].  
2.3.2 Rotavirus disease  
 
Acute gastroenteritis caused by rotavirus infection is a significant cause of childhood 
morbidity and mortality, resulting in ~ 220,000 deaths of young children below 5 years of age 
in SSA each year[56, 57]. Although the greatest burden of rotavirus disease and mortality 
occurs in Asia, SSA has the highest rates of rotavirus-associated mortality in young children, 
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and rotavirus is thought to account for a third of diarrheal hospital admissions in African 
infants [58, 59].  In a study in Kilifi District, Kenya, group A rotavirus alone was responsible 
for 38% of hospital admissions of infants for diarrhea with an incidence of 1,431 cases per 
100,000 person-years[60]. 
Although the incidence of rotavirus infection is highest in children aged 6 months to 2 
years of age, infection has been known to occur in neonates and infants younger than 2 
months[61, 62]. In developing countries in Africa and Asia, rotavirus infection and disease 
occur early in life and 75% of infants will acquire rotavirus infection during the first year of 
life, with 81% of children hospitalized for rotavirus diarrhea being less than 1 year of age [63, 
64]. Rotavirus is thought to be the single most common cause of  diarrhea, contributing to as 
much as a quarter of all diarrheal cases in both outpatient and inpatient African children. 
There is substantial overlap between high HIV disease burden and diarrheal case fatality, 
with the countries most heavily burdened by HIV experiencing the highest diarrheal case 
fatality[65]. In addition, both HIV-infected and HEU infants are at a higher risk of 
developing diarrhea and of having poorer outcomes following diarrheal episodes[24, 66].  A 
prospective cohort study of infants in the Democratic Republic of Congo demonstrated that 
HIV-1-infected infants had an increased risk of death due to diarrhea when compared with 
HIV-1-uninfected infants and HEU infants had a greater risk of persistent diarrhea when 
compared with HUU infants[24]. 
2.3.3 Measles disease  
Despite recent progress in measles control in the developing world due to mass 
immunizations and supplemental immunization activities (SIAs), measles remains a 
significant cause of morbidity and mortality worldwide, particularly in SSA which accounted 
for 59% of the approximately 454,000 global deaths due to measles in 2004[67]. 
Furthermore, regular transmission of measles continues in many of the countries where the 
HIV-1 disease burden is high. Infants born to HIV-1-infected women are at a higher risk for 
measles infection compared to HUU infants, and are susceptible at a younger age [68], before 
administration of the live attenuated measles vaccine at 9 months of age.  In these children, 
infection is associated with a greater severity of measles that is more likely to result in death, 
regardless of the infant’s own HIV-1 infection status [68-71]. This is thought to be due to the 
lower levels of measles-specific trans-placental antibody transfer demonstrated in these 
infants[72, 73].  
Concerns about inadequate transfer of passive immunity to HIV-1-exposed infants 
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and the inability of HIV-1-infected infants to mount a protective immune response against 
measles, suggest that HIV-1 may be a potential barrier to the elimination of measles[74, 75].  
This is of particular concern as HIV-1 infected children have been shown to have prolonged 
measles virus RNA shedding, and with improved survival due to increased access to pediatric 
antiretroviral therapy, these children could form a large pool of infectious individuals with 
potential for causing measles outbreaks[76, 77]. One study demonstrated that even when viral 
suppression has been achieved through use of ART, responses to revaccination waned over 
time, with the proportion of children with detectable antibody dropping from 98% to 60%  at 
one and 24 months post-revaccination, respectively[78]. Indeed the resurgence of measles 
outbreaks in 28 (61%) of 46 SSA countries in 2009-2010 compared to 9 in 2008, despite 
improved and sustained measles vaccination coverage (MCV) (Figure ), show fragility of 
gains made towards eliminating measles on the continent and it is thought that this may be 
linked to the HIV-1 epidemic[75, 79, 80]. Leveling off of MCV since 2010 is of concern, as it 
implies a slackening of progress towards elimination of measles. Global measles outbreaks 
have occurred in the past 2 years in all WHO regions, with SSA experiencing a 100% 
increase in measles incidence. Whereas the largest increases occurred in Europe and the US, 
there are concerns that transmissibility of the virus, sub-optimal measles vaccination 
coverage, and increasing vaccine hesitancy may wipe out progress made in the past 15 years 
and slow down or reverse any gains made towards the global elimination of measles[81, 82].  
 
Figure 5 Number of reported measles cases and coverage with the first dose of 
measles containing vaccine  in children below 1 year, WHO African region 2000-2010[83] 
 
 
2.4 PASSIVE TRANSFER OF MATERNAL ANTIBODIES 
Before mounting their own immunity to pathogens commonly occurring in a child’s 
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environment, infants are protected by maternal antibodies transferred across the placenta and 
through breast milk. The efficiency of transplacental transfer is affected by multiple factors, 
including maternal immunization status and antibody levels, infections such as HIV-1 and 
placental malaria, and infant gestational age and birthweight[39, 40, 84].  In HIV-1-infected 
individuals, memory B cell function that is important in antigen-specific antibody production 
is defective[36]. This, coupled with hypergammaglobulinemia due to abnormal 
immunoglobulin G (IgG) production by hyperactivated naïve B cells, may result in 
insufficient and inefficient maternal antibody transfer across the placenta[37].   
Although HEU infants have higher immunoglobulin levels compared to HUU infants, 
pathogen specific antibody levels are found to be lower, particularly in the presence of high 
systemic viral load in the mother[41]. This has been demonstrated for several pathogens 
including tetanus, measles virus, and S. pneumoniae[40, 43-46].  Therefore, infants born to 
HIV-1-infected women represent a vulnerable population with increased risk of infectious 
disease morbidity and mortality, and this vulnerability is thought to contribute to the up to 4-
fold higher mortality they experience in the first year of life[15, 23, 47, 48]. HIV-1 viral load 
and HIV-1-specific IgG antibody levels are inversely associated with  placental transfer of 
anti-measles IgG, thus suggesting that advanced maternal disease may compromise placental 
transfer[41].  There is evidence that some humoral immune reconstitution occurs following 
initiation of antiretroviral therapy particularly if initiated early in HIV disease[36], and this 
benefit could be transferred via the placenta. 
Besides the effect on antibody transfer via the placenta, HIV-1 disease may decrease 
the ability of breast milk to protect infants against infections. HIV-1 infection results in rapid 
and persistent depletion of gut-associated CD4+ T cells[85] and has been associated with 
decreases in immunoglobulin A (IgA) producing B cells in the intestines[86]. A reduction in 
these cells may affect the levels of breast milk IgA, as IgA production is thought to occur in 
B cells with homing profiles similar to that of B cells found in the gut associated lymphoid 
tissue (GALT). Should this be the case, the immunological resources in breast milk could 
therefore be compromised.  Studies that have demonstrated no association between mode of 
infant feeding and morbidity or mortality in infants born to HIV-infected women[87, 88] 
support the hypothesis that breast milk from HIV-infected women may not confer adequate 
protection against infections.  However, this finding was not confirmed in a recent study[89], 
where B cells with homing markers suggesting gut origin were equally identified in  breast 
milk of HIV-infected and uninfected women, suggesting that HIV does not diminish the 
immune profile of breast milk. Likewise, a comparison of breast milk from HIV-infected and 
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uninfected women[28] found that Haemophilus influenzae, Campylobacter jejuni, 
Helicobacter pylori, and S. pneumoniae IgG and IgA levels were similar in the two groups, 
while in another study HIV-infected women had higher total IgG levels, but similar total IgA 
levels to uninfected women[90].  
Infant feeding recommendations for HIV-1 infected women have evolved over time 
alongside interventions to initially decrease and now eliminate MTCT of HIV. As 
breastfeeding is a key infant survival strategy in resource limited settings, women are advised 
to practice exclusive breastfeeding (EBF) during the first 6 months of an infant’s life to 
minimize HIV-1 transmission risk and maximize breast milk benefits to the baby. Potential 
mechanisms for reduced HIV-1 transmission associated with EBF include 1) a reduction in 
dietary antigens and enteric pathogens that may maintain the integrity of the intestinal 
mucosal barrier, thus limiting inflammatory responses to the gut mucosa, and 2) promotion of 
beneficial intestinal micro flora that may increase resistance to infection and modulate the 
infant’s immune responses[91]. Either mechanism may limit the passage of breast milk virus 
from the gut to the systemic and lymphatic circulation. In addition, continuous complete 
emptying of the breast in women practicing EBF contributes to maintenance of mammary 
epithelial integrity. This reduces the likelihood of both clinical and sub-clinical mastitis, 
which are associated with a 2-4 fold increased HIV-1 transmission risk due to altered breast 
milk cellular composition, increased breast milk virus and altered local defenses within the 
breast [92],[93, 94]. EBF is especially attractive in this era when efficacious antiretroviral 
regimens are available and recommended for all HIV-1 infected women regardless of their 
immunological status, in order to diminish transmission risk during pregnancy and 
breastfeeding.  
Some studies have demonstrated important immunological breast milk benefits for 
HEU infants in resource limited settings with a reduction of pneumonia incidence and all-
cause mortality[95-98]. However, there are no studies to date of the effect of ARVs on 
immunological components of breast milk.   
Despite recommendations to exclusively breastfeed, EBF rates remain low in many 
parts of the world[99]. Data from the Kenya Demographic and Health Survey (KDHS) 2013 
shows that there had been an improvement since previous surveys. However,  the EBF rate of 
84% at 1 month dropped rapidly to 63% at 3 months and 7.6% at 6 months, with a median 
EBF duration of 3.3 months[100]. Therefore, besides the need to continue to promote EBF 
uptake, further work is needed to investigate the effect of maternal ART on pathogen-specific 
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specific IgA levels in breast milk and the impact this would have on infant morbidity and 
mortality, taking into account potential confounding factors such as intensity and duration of 
breastfeeding, and infant vaccination and HIV infection status.  
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3 AIMS 
The broad goal of this thesis was to determine the contributions of antiretroviral prophylaxis 
and breastfeeding practices on transfer of maternal antibodies and their impact on infant 
health. We hypothesized that 1) by restoring maternal immune function and reducing HIV-1 
viral load through triple ART compared to standard short course treatment, systemic and 
breast milk pathogen specific antibody levels and their passive transfer will increase  2) 
infants born to mothers who receive triple ART will have less morbidity and mortality and 
this advantage will be dependent on the intensity of breastfeeding  3) providing HIV-1 
infected women with intensive counseling will increase the proportion who practice exclusive 
breastfeeding. To answer our research questions, we developed the following aims: 
Study I. To compare changes between antenatal enrolment and delivery in total and pathogen 
specific IgG levels (measles, Rotavirus and S. pneumoniae) and in trans-placental transfer 
between women who received triple ART prophylaxis and those who received a short-course 
regimen. 
Study II. To compare breast milk IgA levels in women randomized to triple ART versus the 
standard short-course regimen at 2 weeks after delivery and longitudinally. 
Study III. To determine association of maternal treatment with infant morbidity and 
mortality. 
Study IV. To investigate effectiveness of intensive counseling on breastfeeding practices 
among HIV-1 infected women at 3 months post-partum. 
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4 RESEARCH APPROACH 
4.1 STUDY DESIGNS 
We answered our research questions using 2 studies conducted in Kenya. The first 3 
aims, were nested within the Kesho Bora study[101], which was a multi-site randomized 
clinical trial (RCT) conducted between 2004 and 2009. HIV-1-infected pregnant women 
identified prior to 32 weeks gestation were recruited and followed up together with their 
infants for 12-18 months after delivery. The main study had two sites in Kenya, one in 
Burkina Faso, and two in South Africa. The three studies reported in this thesis used data and 
samples from the Kenyan sites, Nairobi and Mombasa.  
For the last aim, we used data from a before-after study conducted in Nairobi, to determine 
whether providing intensive breastfeeding counseling to HIV-infected pregnant women 
would improve the proportion who practice exclusive breastfeeding. 
We intentionally developed these two studies to meet the needs of our research 
questions. Thus, the participants in the RCT were a healthy and select group who received 
care in well-equipped research facilities with highly trained health personnel. On the other 
hand, the before-after study took place in a real-world setting and participants received care 
that was not different than that which they would have received if they had not participated in 
a research study.  
4.2 INCLUSION CRITERIA, PARTICIPANT RECRUITMENT AND FOLLOW UP 
 
Besides confirmed HIV diagnosis, willingness to provide informed consent, and to be 
randomized, additional criteria for study participation in the RCT included  
 No evidence of clinically significant conditions (obstetric, cardiac, respiratory 
[including active tuberculosis], hepatic, gastrointestinal, endocrine, renal, 
haematologic, psychiatric, neurologic, or allergic) requiring care which could 
interfere with study interventions 
 Not taking ARVs at the time of presentation for possible enrolment 
 Capacity and willingness to participate in all follow-up visits, clinical 
exminations and agreement to venipuncture for themselves and their children 
 Residency in site catchment area until two years after delivery 
 Willingness and no contraindications to receive ARVs, namely: 
o Severe anemia (hemoglobin <7gm/dl) 
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o Severe neutropenia (neutrophil count <750*106 cells/l)   
o Blood alanine amino transferrase >5 times upper limit of normal 
(ULN)  
o Amylase >2 times ULN 
o Blood creatinine >3 times ULN 
o Known allergy to one of study ARVs or to benzodiazepines 
o Treatment with anticoagulants, benzodiazepines, rifampicin, 
magnesium sulphate, corticosteroids for more than 7 days at the time 
of planned enrolment. 
Women were randomized to one of two MTCT prophylaxis regimens: (1) triple prophylaxis  
using 300 mg Zidovudine (ZDV), 150 mg lamivudine (3TC), and 400 mg/100 mg 
lopinavir/ritonavir (Kaletra) given twice daily beginning at 28-36 weeks gestation until six 
months postpartum, or (2) a short-course regimen consisting of 300 mg ZDV given twice 
daily from 28-36 weeks gestation until the onset of labor, when one dose each of 600 mg 
ZDV and 200 mg Nevirapine (NVP) were administered.  All infants received one dose NVP 
(2 mg/kg oral suspension) preferably within 72 hours of birth, but no later than 7 days after 
birth. In addition, infants born after December 2006 received twice daily zidovudine in the 
first week of life.  
After initiation of treatment/prophylaxis, follow-up visits occurred every week until 
delivery. Three to five days after delivery, the women received a home visit. Women and 
their infants were then followed up in clinic every two weeks until eight weeks postpartum, 
then every month until one year postpartum and quarterly thereafter.  At each visit, 
questionnaires were administered to obtain socio-demographic and clinical information and 
clinical examinations were conducted by medical doctors. In addition, maternal and infant 
blood, cord blood, and breast milk specimens were collected over the course of follow-up.  
Maternal interviews and medical records were utilized to determine morbidity and mortality 
in infants.  In the study overall, cumulative 12 month follow-up was 92% in the triple ART 
arm and 90.5% in the short-course arm.  
For the before-after study, women attending antenatal clinics were routinely offered 
counseling and testing for HIV-1. After counseling on available PMTCT interventions, 
women identified as HIV-1-infected women chose freely how they planned to feed their 
infants. After receiving information about the study, those who planned to breastfeed their 
infants, met the following criteria and were willing to participate and provided informed 
consent, were enrolled into the study: 
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 Age ≥ 18 years (minimum legal age for informed consent in Kenya) 
 Gestation by dates  less than 36 weeks 
 Absolute CD4 count greater than 200 cells/mm3 
 Planning to deliver in Nairobi and to stay in the study area for 3 months postpartum  
At enrolment, a questionnaire was administered to obtain sociodemographic information and 
women were seen weekly until delivery. Thereafter, they were seen together with their infants 
at 1, 6, and 10 weeks, and again at 3 months, at which times questionnaires were 
administered and clinical examinations were conducted by nurse counselors. The week 6 and 
week 10 visits were timed to coincide with times when the mother would be bringing her 
baby to clinic for immunization or coming to access family planning services. Women in the 
control (before) group received standard of care while those in the intervention (after) group 
received additional breastfeeding counseling antenataly, and at 1 and 6 weeks postpartum by 
peer counselors (HIV-infected women with experience in exclusive breastfeeding) who were 
not involved in questionnaire administration or clinical examination.  
4.3 APPROACHES TO STATISTICAL ANALYSIS 
 
Linear Regression  
Linear regression is a suitable analytic approach for a quantitative continuous 
outcome variable. The use of a linear regression model assumes that the relationship between 
the outcome and the explanatory variable is linear, that the observations are independent, and 
that for any value of the explanatory variable, the distribution of the outcome variable is 
normal. The variance of the outcome is also assumed to be constant across different values of 
explanatory variables. After fitting the model, it is appropriate to formally test whether these 
assumptions hold. In some cases, data transformations may be necessary to achieve 
normality. 
Kaplan Meier estimator 
The Kaplan-Meier estimator curve is a popular non-parametric method used to 
estimate and display survival function for time-to event variables, in the presence of 
censoring. The use of the Kaplan Meier method assumes that censoring is independent of the 
likelihood of failure (i.e. that the event of interest happens) and that the survival probabilities 
are comparable in the individuals in the sample. Once the survival times have been estimated 
 18 
and the survival curves drawn for different groups of subjects, they can be formally compared 
using the log-rank test. 
Cox proportional hazards regression 
This approach is useful for time-to event data when we want to assess the effect of 
risk factors on the survival time. It models the “hazard” which is the instantaneous incidence 
rate. It is only valid under the proportional hazards assumption, which states that the hazard 
ratio between the two groups compared is constant over time, and that the survival times 
between individuals in the sample are independent. The proportionality assumption should be 
formally checked to see if it holds, for example, by using Shoenfield residuals.  
Poisson/negative binomial regression 
When the outcome variable is a count, Poisson regression is the classical method used 
to assess the association with risk factors. A variable with Poisson distribution has a mean 
equal to its variance. Where over-dispersion is present (the mean is significantly different 
from the variance), it is best to use alternative  approaches such as the negative binomial 
regression or the Quasi-poisson, which are more robust.  
Log Binomial regression 
A commonly used measure of association for binary outcomes in epidemiological 
investigations is the relative risk or risk ratio (RR). It measures the probability of disease 
among the exposed individuals relative to the probability of disease among the unexposed. 
When the outcome is rare, logistic regression can be used, as the odds ratio (OR) so obtained 
closely approximates the RR. However, when the response outcome is common (where 
incidence >10%), there is wide divergence between the OR and the RR. In such cases, the 
log-binomial regression is more suitable. However, it is important to bear in mind that the 
log-binomial can produce narrower confidence intervals (thus exaggerating the certainty of 
the point estimate) and the iterative method of implementation can fail to converge. 
Repeated measures 
When we have several measures of the same individual, or different measures of 
different individuals within the same cluster, we have to account for the between-subject 
variability as well as for the within-subject variability. Ignoring dependence between the 
observations will underestimate the standard errors of the time-dependent explanatory 
variables. Standard regression models are therefore not applicable. Instead, specific methods 
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such as the repeated-measures analysis of variance (ANOVA), generalized estimating 
equations (GEE), or linear mixed models are used. 
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4.4 ETHICAL CONSIDERATIONS 
 
It would currently be unethical to conduct the RCT that is providing the data for 
studies I-III. This is because the findings from the main study indicated that triple ART is 
superior to short-course zidovudine in preventing transmission of HIV from the mother to her 
child. The current practice, therefore, is to put all HIV-1-infected women on triple 
antiretroviral therapy as soon as the HIV diagnosis is made, both for their own health and that 
of their children. However, these data provide us with a unique opportunity to answer an 
important question concerning the immunological effect of this treatment and impact on 
infant health. Nevertheless, there are some concerns that ARV exposure in utero may 
contribute to some of the vulnerability of HEU children, and the long-term effect of ARV 
exposure on the child’s immune system development. This is a question that will not be 
answered easily; while it may be possible to examine effects of ARV exposure by comparing 
children exposed to ARV drugs with those born to ARV naïve women using historical 
cohorts, it is not possible to tease out the independent effect of exposure to HIV on the child’s 
immunological development. We are therefore left to wait for data to accrue on the long term 
effects of ARVs on the child’s health. 
In conducting the breastfeeding study whose data we have used for study IV, there are 
3 ethical issues that arose. One was the involvement of the male partners. The majority of  the 
women did not want their male partners involved, as this could disclose their HIV status to 
their partners, and they cited concerns about intimate partner violence or relationship 
dissolution due to economic dependence on the male partner. However, this meant that the 
woman forfeited partner support for negotiating management of her infection and protecting 
her child from becoming infected. Male partner support has been shown (and was found in a 
related publication) to be associated with better infant outcomes, therefore there are infants 
who either became HIV infected or died who might have survived HIV-free.  In addition, 
non-disclosure puts the woman’s sexual partner(s) at risk for becoming HIV infected.  
Secondly, there is a perception by the communities that EBF is for HIV infected 
women. Therefore, HIV-positive women risk inadvertent disclosure of HIV status by their 
commitment to exclusively breastfeed their infants, or may jeopardize their infants’ health 
should they give into the pressure to mix feed.  On the other hand, in an effort to prove to 
their friends, neighbors, and family that they are not HIV-infected, many HIV-negative 
women living within these environments practice mixed feeding. This is unfortunate, as it 
puts their children at risk for poor growth and development, and increased morbidity and 
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mortality. In addition, because these women are at risk for HIV infection themselves, it puts 
their infants at a higher risk of becoming HIV infected, should the mother contract HIV later 
in pregnancy or during the breastfeeding period. 
Thirdly, there are high levels of stigma associated with a positive HIV diagnosis. This 
necessitated HIV-positive women to make difficult and burdensome choices to succeed in 
meeting their breastfeeding goals. These included changing their residency in order to not go 
against community norms to mix feed, avoiding social or extended family gatherings which 
may put them under undue pressure to mix feed, and never going anywhere without their 
child, as any other caregiver could potentially violate the feeding practices even when there 
was a sufficient quantity of expressed breast milk for the child.  These had consequences for 
the family including the woman’s inability to earn income and forfeiting social support that 
would be beneficial to her coping with her HIV diagnosis and providing optimum care to her 
child. 
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5 RESULTS 
In this population of HIV-infected women with moderate immunosuppression, we 
found non-significant declines in pathogen-specific maternal serum antibody levels during 
pregnancy. IgG levels were comparable at delivery between the two arms. In a subset of the 
women who had cord blood available, women in triple ART transferred higher levels of 
pathogen specific antibody levels. Women who were more immunosuppressed, as indicated 
by higher total immunoglobulin levels, transferred lower levels of pathogen specific 
antibodies. Antibody transfer was positively correlated with pathogen specific antibody levels 
in maternal plasma. 
We found no effect of treatment on breast milk levels of IgA to measles and rotavirus 
in transitional milk obtained at two weeks post-partum. In addition, there was no effect of 
treatment on IgA levels in mature milk obtained at 14 weeks and at 5 months postpartum.  
Women with higher serum measles IgG were more likely to have high measles IgA levels 
with a trend for more immunosuppressed women to have lower levels. Women with higher 
serum rotavirus IgG levels, and who took antiretroviral prophylaxis for longer duration prior 
to delivery, had higher rotavirus IgA levels. The strongest association with rotavirus IgA 
levels was primigravida which was inversely associated with rotavirus IgA levels. 
We found no effect of treatment on diarrhea, pneumonia, hospitalization, or death. 
Triple ART was associated with a 2-fold increased risk for acute lower respiratory infection. 
For all three morbidity outcomes, we found a higher risk for male infants, and low 
birthweight infants had an almost 4-fold increased risk for pneumonia. Breastfeeding and 
being on ARV for 30 days or more during pregnancy were protective for acute infectious 
morbidity. 
We found high levels of EBF among HIV-infected women. While the levels were not 
different between control and counseling intervention groups, they were higher than the 
Kenyan general population averages. 
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6 DISCUSSION AND CONCLUSIONS 
Our finding of no effect of treatment on diarrhea, pneumonia, hospitalization or 
mortality while not being the result we hoped for is nevertheless an important finding. First, 
slow immune reconstitution following initiation of ARV use necessitates being on treatment 
for longer periods of time to reverse the effects of HIV infection and realize the beneficial 
effect of treatment. In addition, the narrow range of CD4 count of the women in the study and 
their overall good health may have resulted in a group of women in whom it is more difficult 
to detect an effect of treatment. There is a paucity of data on IgG transfer levels for 
uninfected women, making interpretation of our findings challenging. However, it is 
encouraging that levels of measles IgG that were transferred are within the range of what has 
been reported for uninfected women. We could therefore postulate that this beneficial effect 
may extend to the other immunoglobulins for which we do not have general population data 
for comparison.  
The finding that socioeconomically advantaged primigravid women had lower 
rotavirus IgA levels than multiparous women is an interesting finding that may be reflective 
of the immunological integration that occurs between a mother and her child during 
breastfeeding in order to provide targeted protection to environmental exposures. It may be 
for this reason that breast milk is an important child survival strategy in resource limited 
settings, where it is thought that more children have died for lack of breastfeeding than from 
HIV infection. Therefore, maximizing breast milk benefits by improving maternal health and 
nutrition, and practicing safe breastfeeding practices is important for HEU children.   
The high levels of exclusive breastfeeding rates among HIV-infected women is an 
important finding. It shows that with support, women are amenable to change with regard to 
infant feeding practices.  Extension of this benefit to all women irrespective of their HIV 
status could be achieved by reducing EBF stigma, and providing other targeted interventions 
to mitigate EBF challenges including increasing male partner involvement and support.  
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7 FUTURE PERSPECTIVES 
Optimizing the health of the growing population of HEU children remains an 
important pursuit. Larger prospective studies involving HEU children from diverse 
backgrounds will help better understand whether their vulnerability to infectious disease 
morbidity and mortality was more a function of untreated HIV infection in the mother or 
whether it is still a concern in the era of efficacious ART especially when initiated prior to 
conception. These studies will need to include unexposed uninfected children from similar 
socioeconomic environments in order to make suitable comparisons in their health outcomes. 
Beyond early childhood, there is a need to understand long term growth and developmental 
effects of HIV and ART exposure. 
In addition, we still don’t know that much about breast milk and mucosal immunity. 
Future studies may need to take a more holistic approach to breast milk characterization 
linked to infant outcomes to better understand its role and mechanism in infant immune 
system development. Alongside this there is need to understand contextual barriers to EBF 
practice and to continue promoting safer breastfeeding practices among all women 
irrespective of their HIV-infection status. Such a universal approach would create a more 
supportive environment for women to meet their breastfeeding goals. 
As pediatric HIV disease transitions from one with high incidence and mortality to 
one with low incidence, there is need to continue to investigate patient, health provider and 
health system factors that contribute to the excess mortality experienced by HEU children. 
Studies that take into account regional differences in these factors are necessary in order to 
design more effective interventions to optimize the health of all children. 
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